DEFINITY

Case Studies


Case Study Programs

Getting to the Bottom of the Problem
The Importance of Endocardial Border Delineation of the LV Myocardial Apex
Presented by:
Vincent Sorrell, MD
Natesa Pandian, MD

View Presentation


Interactive Case Studies

38 Year Old Woman Considered For Gastric Bypass Surgery
Images courtesy of M. Vannan, MBBS

38 Year Old Man With End Stage Renal Disease
Images courtesy of M. Vannan, MBBS

66 Year Old Woman With Increasing Heart Failure Symptoms
Images courtesy of M. Vannan, MBBS

47 Year Old Woman Presenting With Chest Pain
Images courtesy of Roberto Lang, MD, University of Chicago
Noninvasive Cardiac Imaging Laboratories

43 Year Old Man With Hypertension And HIV
Images courtesy of Regions Hospital, St. Paul MN

38 Year Old Woman With History of Myocardial Infarction
Images courtesy of Roberto Lang, MD, University of Chicago
Noninvasive Cardiac Imaging Laboratories

Case Study

Case Studies

Do you have DEFINITY® case studies you would like to share with us?

Please contact us to discuss


INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING:  Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [See WARNINGS AND PRECAUTIONS (5.1)].  Most serious reactions occur within 30 minutes of administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration [See CONTRAINDICATIONS (4)].

  • Always have resuscitation equipment and trained personnel readily available.


In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration [See ADVERSE REACTIONS (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [See Postmarketing Experience (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

 

HOME